PharmaCielo Ltd.
PCLO.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.90M | 1.19M | 738.60K | 1.14M | 2.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.90M | 1.19M | 738.60K | 1.14M | 2.08M |
| Cost of Revenue | 1.89M | 1.71M | 1.91M | 2.16M | 2.74M |
| Gross Profit | 18.30K | -514.60K | -1.17M | -1.02M | -658.70K |
| SG&A Expenses | 4.18M | 4.69M | 5.03M | 6.18M | 7.01M |
| Depreciation & Amortization | 187.00K | 212.70K | 257.20K | 253.40K | -375.90K |
| Other Operating Expenses | -44.30K | -47.00K | -48.40K | -61.50K | -61.50K |
| Total Operating Expenses | 6.21M | 6.57M | 7.14M | 8.53M | 9.31M |
| Operating Income | -4.30M | -5.37M | -6.40M | -7.39M | -7.23M |
| Income Before Tax | -10.31M | -10.43M | -11.22M | -12.06M | -9.51M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.31 | -10.43 | -11.22 | -12.06 | -9.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.31M | -10.43M | -11.22M | -12.06M | -9.51M |
| EBIT | -4.30M | -5.37M | -6.40M | -7.39M | -7.23M |
| EBITDA | -4.12M | -4.95M | -5.75M | -6.56M | -6.40M |
| EPS Basic | -0.06 | -0.06 | -0.07 | -0.08 | -0.06 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.04 | -0.03 |
| EPS Diluted | -0.06 | -0.06 | -0.07 | -0.08 | -0.06 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.04 | -0.03 |
| Average Basic Shares Outstanding | 667.32M | 667.32M | 654.43M | 640.25M | 626.51M |
| Average Diluted Shares Outstanding | 667.32M | 667.32M | 654.43M | 640.25M | 626.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
